Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Oxford Biomedica (Us) LLC currently manages 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 3 distinct examiners. The prosecution activity is spread across 2 distinct art units, showing technical variety in the company's pending applications.
The busiest examiner for the company is BLUMEL, BENJAMIN P, who is responsible for 1 pending office action. This represents one-third of the total 3 pending office actions currently active for the company. Each of the 3 distinct examiners is handling exactly one of the pending matters.
The presence of the current pending office actions in the Biotechnology & Pharmaceuticals sector indicates an ongoing effort to secure patent rights. BLUMEL, BENJAMIN P is one of the 3 distinct examiners involved, managing 1 pending office action. The distribution across 2 distinct art units suggests that the company's applications involve different technological focuses.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BLUMEL, BENJAMIN P | 1 | 70.8% | +30.5% |
| GONZALES, JOSEPHINE MARIA | 1 | 26.6% | +38.4% |
| GILL, RACHEL B | 1 | 65.6% | +28.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18066567 | METHODS AND COMPOSITIONS FOR THE PRODUCTION OF ADENO-ASSOCIATED VIRUS | GONZALES, JOSEPHINE MARIA | 69d |
| 18940528 | Deamidation Depleted Adeno-Associated Virus Product | BLUMEL, BENJAMIN P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17821884 | ADENO-ASSOCIATED VIRUS FORMULATIONS | GILL, RACHEL B | 29d |
| 18066567 | METHODS AND COMPOSITIONS FOR THE PRODUCTION OF ADENO-ASSOCIATED VIRUS | GONZALES, JOSEPHINE MARIA | 69d |
| 18940528 | Deamidation Depleted Adeno-Associated Virus Product | BLUMEL, BENJAMIN P | — |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18940528 | Deamidation Depleted Adeno-Associated Virus Product | BLUMEL, BENJAMIN P | — | §102§103§112 | Non-Final OA | — | Pending | Nov 07, 2024 |
| 18066567 | METHODS AND COMPOSITIONS FOR THE PRODUCTION OF ADENO-ASSOCIATED VIRUS | GONZALES, JOSEPHINE MARIA | 1631 | §102§103 | Non-Final OA | 69d | Pending | Dec 15, 2022 |
| 17821884 | ADENO-ASSOCIATED VIRUS FORMULATIONS | GILL, RACHEL B | 1671 | §103 | Final Rejection | 29d | Pending | Aug 24, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial